Amphetamine

Amphetamine

SCHEMBL4070210

CC(N)Cc1ccccc1.Cl.Cl

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC6A2SLC6A3

The experimentally established mechanism targets of Amphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SLC6A2 known ✓ P23975 4/20 0.95
SLC6A3 known ✓ Q01959 2/20 0.95
TAAR1 Q96RJ0 4/20 0.95
SLC6A4 P31645 3/20 0.95
MAOA P21397 1/20 0.95
SIGMAR1 Q99720 1/20 0.95
CYP2A6 P11509 1/20 0.95
ADORA2A P29274 1/20 0.95
ADORA1 P30542 1/20 0.95
CYP2D6 P10635 1/20 0.64
EPHX1 P07099 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dextroamphetamine SCHEMBL1042914 1.00 SLC6A2 (0.95) SLC6A2TAAR1SLC6A4SLC6A3MAOA
Levamfetamine SCHEMBL4070216 1.00 SLC6A2 (0.95) SLC6A2TAAR1SLC6A4SLC6A3MAOA
Levamfetamine SCHEMBL573666 1.00 SLC6A2 (0.95) SLC6A2TAAR1SLC6A4SLC6A3MAOA
Amphetamine SCHEMBL27581784 1.00 SLC6A2 (0.95) SLC6A2TAAR1SLC6A4SLC6A3MAOA
Amphetamine SCHEMBL573665 1.00 SLC6A2 (0.95) SLC6A2TAAR1SLC6A4SLC6A3MAOA
Dextroamphetamine SCHEMBL9114306 1.00 SLC6A2 (0.95) SLC6A2TAAR1SLC6A4SLC6A3MAOA
Amphetamine SCHEMBL15094242 0.97 SLC6A2 (1.00) SLC6A2TAAR1SLC6A4SLC6A3MAOA
Amphetamine SCHEMBL1560962 0.97 SLC6A2 (1.00) SLC6A2TAAR1SLC6A4SLC6A3MAOA
Levamfetamine SCHEMBL9673275 0.97 SLC6A2 (1.00) SLC6A2TAAR1SLC6A4SLC6A3MAOA
Dextroamphetamine SCHEMBL8859 0.97 SLC6A2 (1.00) SLC6A2TAAR1SLC6A4SLC6A3MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019136224-A1 AMPHETAMINE-GUANFACINE COMBINATIONS FOR TREATMENT OF NEUROPSYCHIATRIC DISORDERS SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2019-07-11 WO disclosed
EP-2109465-A2 POLAR HYDROPHILIC PRODRUGS OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME Kempharm, Inc. (US) 2009-10-21 EP disclosed
EP-2101571-A1 NON-STANDARD AMINO ACID CONJUGATES OF AMPHETAMINE AND PROCESSES FOR MAKING AND USING THE SAME Kempharm, Inc. (US) 2009-09-23 EP disclosed
WO-2008098151-A2 POLAR HYDROPHILIC PRODRUGS OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME KEMPHARM, INC. (US) 2008-08-14 WO disclosed
WO-2008073918-A1 NON-STANDARD AMINO ACID CONJUGATES OF AMPHETAMINE AND PROCESSES FOR MAKING AND USING THE SAME KEMPHARM, INC. (US) 2008-06-19 WO disclosed
EP-0634999-A4 NOVEL AMPHETAMINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE AMPHETAMINE DERIVATIVE CONJUGATES AND LABELS. 1995-02-01 EP disclosed
EP-0634999-A1 NOVEL AMPHETAMINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE AMPHETAMINE DERIVATIVE CONJUGATES AND LABELS BIOSITE DIAGNOSTICS INC. (US) 1995-01-25 EP disclosed